BTAI
BioXcel Therapeutics, Inc. NASDAQ Listed Mar 8, 2018$1.23
Mkt Cap $33.3M
52w Low $1.01
3.1% of range
52w High $8.08
50d MA $1.34
200d MA $2.18
P/E (TTM)
-0.2x
EV/EBITDA
-2.0x
P/B
—
Debt/Equity
-1.1x
ROE
73.2%
P/FCF
-0.3x
RSI (14)
—
ATR (14)
—
Beta
0.30
50d MA
$1.34
200d MA
$2.18
Avg Volume
1.5M
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
555 Long Wharf Drive · New Haven, CT 06511 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.34 | -0.58 | -70.6% | 1.37 | +3.6% | -8.0% | -4.0% | +10.7% | -9.0% | -3.3% | — |
| Nov 12, 2025 | AMC | -1.54 | -2.18 | -41.6% | 1.71 | +0.0% | -5.8% | +1.2% | +12.3% | +0.5% | -5.4% | — |
| Aug 12, 2025 | AMC | -2.30 | -2.45 | -6.5% | 6.80 | +7.2% | -17.6% | -15.2% | +15.4% | +3.5% | -13.2% | — |
| May 12, 2025 | AMC | -2.72 | -1.50 | +44.9% | 1.48 | +0.0% | -3.4% | -4.2% | +6.6% | -0.7% | -0.7% | — |
| Mar 27, 2025 | AMC | -4.36 | -3.57 | +18.1% | 2.31 | -2.2% | -8.2% | -4.2% | -5.4% | +3.6% | -8.5% | — |
| Nov 14, 2024 | AMC | -8.00 | -5.12 | +36.0% | 8.33 | +4.9% | +9.1% | +2.1% | +3.9% | -2.4% | -3.0% | — |
| Aug 6, 2024 | AMC | -12.16 | -3.36 | +72.4% | 15.36 | +5.2% | -5.1% | -10.0% | -10.8% | -10.1% | +5.7% | — |
| May 9, 2024 | AMC | -10.88 | -13.92 | -27.9% | 36.88 | +0.7% | -9.3% | +4.5% | -2.5% | -3.3% | +1.5% | — |
| Mar 12, 2024 | AMC | -15.68 | -12.16 | +22.4% | 44.32 | +1.1% | +3.6% | +0.0% | -6.6% | +2.2% | -0.7% | — |
| Nov 14, 2023 | AMC | -20.64 | -27.52 | -33.3% | 67.52 | +0.7% | +4.3% | -3.4% | -2.8% | -7.3% | +1.8% | — |
| Aug 14, 2023 | AMC | -27.52 | -29.28 | -6.4% | 69.28 | -3.0% | -4.4% | +0.7% | +5.0% | -1.1% | -8.3% | — |
| May 8, 2023 | AMC | -24.96 | -29.44 | -17.9% | 421.28 | -1.8% | +3.5% | +4.8% | -5.3% | +1.5% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.22 | $1.15 | -5.7% | -3.3% | -3.4% | -4.4% | +0.9% | -1.8% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.82 | +10.3% | -2.4% | -8.1% | +16.9% | -10.4% | +1.3% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.11 | $3.00 | -3.5% | +1.9% | -5.7% | -3.0% | +3.8% | -0.7% |
| Sep 12 | Mizuho | Maintains | Neutral → Neutral | — | $3.39 | $3.39 | +0.0% | -8.3% | +1.9% | -5.7% | -3.0% | +3.8% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.96 | $3.91 | -1.3% | +3.5% | -1.2% | -6.2% | -4.7% | -1.4% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.67 | $4.94 | -12.9% | -13.2% | +2.4% | +3.8% | -4.8% | +3.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.75 | $4.65 | -2.1% | +15.4% | +3.5% | -13.2% | +2.4% | +3.8% |
| Jul 15 | LUCID CAPITAL MARKETS | Maintains | Buy → Buy | — | $2.02 | $2.20 | +8.9% | -5.9% | +2.6% | -0.5% | -1.5% | -1.0% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.60 | $1.61 | +0.6% | +3.1% | +4.8% | +18.5% | -1.0% | -12.8% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.28 | $5.12 | -3.0% | -2.1% | +1.0% | -5.7% | -7.3% | +4.8% |
| Jan 7 | BofA Securities | Downgrade | Buy → Underperform | — | $9.17 | $9.12 | -0.5% | -17.8% | -18.2% | -2.1% | +1.7% | -7.0% |
| Jan 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.62 | $6.72 | +1.5% | +38.5% | -17.8% | -18.2% | -2.1% | +1.7% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.05 | $9.24 | +2.1% | -2.9% | +6.0% | -0.5% | +3.6% | +1.8% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.44 | $9.44 | +0.0% | -7.4% | +1.4% | -2.5% | +1.6% | +0.2% |
| Aug 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.16 | $10.01 | -1.5% | -3.1% | +0.8% | -3.2% | -1.7% | -7.4% |
| Aug 9 | UBS | Maintains | Neutral → Neutral | — | $13.12 | $13.28 | +1.2% | -10.8% | -10.1% | +5.7% | -2.3% | +0.2% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.58 | $14.60 | +0.1% | -10.0% | -10.8% | -10.1% | +5.7% | -2.3% |
| Jun 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $21.12 | $20.96 | -0.8% | -3.8% | +0.8% | -8.6% | -4.3% | -3.6% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.88 | $37.12 | +0.7% | -9.3% | +4.5% | -2.5% | -3.3% | +1.5% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.60 | $45.44 | -0.4% | +4.2% | -8.8% | -3.7% | +0.8% | -1.9% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.88 | $43.20 | +0.7% | +2.2% | -0.7% | +2.2% | +1.8% | -0.7% |
| Mar 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $45.92 | $45.60 | -0.7% | +0.0% | -6.6% | +2.2% | -0.7% | +2.2% |
| Mar 13 | BofA Securities | Maintains | Buy → Buy | — | $44.32 | $44.80 | +1.1% | +3.6% | +0.0% | -6.6% | +2.2% | -0.7% |
| Feb 21 | UBS | Downgrade | Buy → Neutral | — | $56.16 | $53.60 | -4.6% | -10.3% | +0.6% | -3.2% | +1.0% | +7.1% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.52 | $68.00 | +0.7% | +4.3% | -3.4% | -2.8% | -7.3% | +1.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.84 | $62.72 | -1.8% | +0.6% | +9.3% | -9.1% | +16.3% | +3.2% |
| Oct 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.28 | $42.72 | -5.7% | +6.0% | +1.0% | +31.7% | +0.6% | +9.3% |
| Oct 5 | Truist | Downgrade | Buy → Hold | — | $42.40 | $39.20 | -7.5% | -0.8% | +6.8% | -2.5% | +21.5% | -2.7% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.44 | $54.40 | +1.8% | +1.2% | +0.9% | -2.1% | -5.4% | -1.3% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.72 | $55.36 | +1.2% | +9.4% | -6.1% | -4.8% | +1.2% | +0.9% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.32 | $64.32 | +0.0% | -4.5% | +1.6% | +0.3% | -3.3% | +1.3% |
| Aug 23 | Mizuho | Maintains | Neutral → Neutral | — | $63.20 | $64.00 | +1.3% | +2.0% | -3.3% | +3.2% | -4.5% | +1.6% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.08 | $68.64 | -2.1% | -1.1% | -8.3% | -0.5% | +2.0% | -3.3% |
| Aug 15 | Truist | Maintains | Buy → Buy | — | $69.28 | $67.20 | -3.0% | -4.4% | +0.7% | +5.0% | -1.1% | -8.3% |
| Aug 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $69.28 | $67.20 | -3.0% | -4.4% | +0.7% | +5.0% | -1.1% | -8.3% |
| Aug 15 | Mizuho | Downgrade | Buy → Neutral | — | $69.28 | $67.20 | -3.0% | -4.4% | +0.7% | +5.0% | -1.1% | -8.3% |
| Aug 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $69.28 | $67.20 | -3.0% | -4.4% | +0.7% | +5.0% | -1.1% | -8.3% |
| Jul 17 | Guggenheim | Downgrade | Buy → Neutral | — | $164.80 | $162.40 | -1.5% | +4.2% | +5.2% | +5.0% | -5.2% | -1.3% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $106.56 | $109.60 | +2.9% | +18.3% | +42.3% | -2.9% | -6.5% | -0.3% |
| Jun 30 | Mizuho | Maintains | Buy → Buy | — | $102.24 | $108.96 | +6.6% | +4.2% | +18.3% | +42.3% | -2.9% | -6.5% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $301.92 | $303.20 | +0.4% | +0.4% | -5.3% | +1.2% | +4.3% | +2.6% |
| May 26 | Goldman Sachs | Maintains | Neutral → Neutral | — | $309.12 | $316.80 | +2.5% | -2.3% | +0.4% | -5.3% | +1.2% | +4.3% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $440.64 | $443.04 | +0.5% | -2.5% | -1.2% | -4.9% | +2.8% | -0.3% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $457.28 | $459.68 | +0.5% | -5.3% | +1.5% | -0.9% | +1.1% | -2.5% |
| May 10 | Mizuho | Maintains | Buy → Buy | — | $436.16 | $452.48 | +3.7% | +4.8% | -5.3% | +1.5% | -0.9% | +1.1% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $421.28 | $413.76 | -1.8% | +3.5% | +4.8% | -5.3% | +1.5% | -0.9% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $301.76 | $308.32 | +2.2% | +2.7% | -7.9% | +2.4% | +0.4% | -2.4% |
| Mar 10 | Jefferies | Downgrade | Buy → Hold | — | $392.96 | $366.24 | -6.8% | -15.9% | +4.0% | -5.4% | -3.6% | -0.8% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $472.48 | $478.08 | +1.2% | +4.1% | +3.8% | -0.3% | -5.9% | +1.0% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $517.44 | $516.80 | -0.1% | -1.5% | -10.2% | +6.7% | -3.2% | +4.1% |
No insider trades available.
8-K
BioXcel Therapeutics, Inc. -- 8-K Filing
BioXcel Therapeutics amended its registration rights agreement and warrant terms, updating governance provisions and investor protections in capital structure dealings.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The vague 8-K filing lacks specific operational or financial details, making it impossible to assess material impact; investors should seek clarification on what event actually triggered this disclosure.
Apr 1
8-K
Unknown — 8-K Filing
BTAI's sNDA submission signals progress toward regulatory approval for a key neuroscience asset, potentially accelerating revenue generation and validating its AI-driven drug discovery platform's commercial viability.
Mar 27
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
BTAI entered a material agreement involving an irrevocable holder commitment valued at $7.8 million, likely indicating secured financing or strategic partnership that could strengthen the company's financial position.
Mar 11
8-K · 8.01
!! High
BioXcel Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
BioXcel Therapeutics submitted an FDA supplemental application for at-home use of IGALMI to treat agitation in bipolar disorder and schizophrenia, potentially expanding the drug's commercial market based on positive clinical trial data.
Feb 12
8-K · 5.02
!!! Very High
BioXcel Therapeutics, Inc. -- 8-K 5.02: Executive Change
BioXcel Therapeutics entered retention and milestone bonus agreements with key executives following FDA approval of IGALMI for at-home agitation treatment, incentivizing leadership continuity during commercialization.
Feb 6
Data updated apr 24, 2026 11:00pm
· Source: massive.com